Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CLDN12 Biologics Sequence Review Report 2026: Claudin-12 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN9 Biologics Sequence Review Report 2026: Claudin-9 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN7 Biologics Sequence Review Report 2026: Claudin-7 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN8 Biologics Sequence Review Report 2026: Claudin-8 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN1 Biologics Sequence Review Report 2026: Claudin-1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN2 Biologics Sequence Review Report 2026: Claudin-2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN5 Biologics Sequence Review Report 2026: Claudin-5 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
BACE2 Biologics Sequence Review Report 2026: Beta-secretase 2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of BACE2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
BACE1 Biologics Sequence Review Report 2026: Beta-secretase 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of BACE1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCL11 Biologics Sequence Review Report 2026: Eotaxin Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CCL11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ALK Biologics Sequence Review Report 2026: ALK tyrosine kinase receptor Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of ALK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADGRF5 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor F5 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of ADGRF5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
1163
1164
1165
1166
1167
>>
2926
>